Simcere anti-rheumatic drug wins SFDA approval
The drug is designed to treat active rheumatoid arthritis and comes under a category of disease modifying anti-rheumatic drugs (DMARDS). The clinical studies demonstrate that Iremod can relieve
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.